ArticleThe Journal of urology2026
Durable Responses and Cystectomy Avoidance With Interleukin-15 Receptor Agonist NAI Plus Bacillus Calmette-Guérin in Bacillus Calmette-Guérin-Unresponsive Nonmuscle-Invasive Bladder Cancer With Carcinoma In Situ ± Papillary Disease.
Article in The Journal of urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
31 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeWe report long-term follow-up on participants in the QUILT-3.032 study in bacillus Calmette-Guérin (BCG)-unresponsive nonmuscle-invasive bladder cancer (NMIBC) carcinoma in situ (CIS) ± papillary disease using nogapendekin alfa inbakicept-pmln (NAI, N-803) approved by the Food and Drug Administration (Anktiva) in combination with BCG. MATERIALS AND
methodsParticipants received 400 mcg NAI in combination with 50 mg BCG through intravesical instillation weekly for 6 weeks, with optional reinduction if complete response (CR) was not achieved at month 3. Primary end point was CR rate at any time; secondary end points were duration of CR, progression-free survival, overall survival, disease-specific survival (DSS), and time to cystectomy.
resultsThe CR rate (n = 100) was 71% (95% CI 61.1-79.6) with a median duration of CR of 26.6 months (range 0.03-53.62). The Kaplan-Meier estimated cystectomy-free rate in the 71 responders at 24 and 36 months was 90.3% (95% CI 79.7-95.6) and 84.2% (95% CI 69.6-92.1), respectively. DSS was 100% (95% CI 100.0-100.0) at 12 months and 98.2% (95% CI 88.2-99.8) at 36 months. Treatment-related adverse events were largely grade 1 to 2 (59%), with 4% grade 3 and no grade 4 or 5 treatment-related adverse events observed with this biological combination.
conclusionsThe CR rate and durability of responses that surpass 53 months reveal the efficacy of NAI in combination with BCG for treating BCG-unresponsive NMIBC with CIS ± Ta/T1 disease. The high cystectomy-free rate of 84% and DSS of 98% at 36 months suggest that NAI plus BCG is a safe and efficacious option for NMIBC with CIS ± Ta/T1 disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.